B Ahrén, R Gomis, E Standl, D Mills, A Schweizer - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—In patients randomized to LAF237, baseline HbA 1c averaged 7.7 ± 0.1% and decreased
at week 12 (Δ = −0.6 ± 0.1%), whereas HbA 1c did not change from a baseline of 7.9 ± 0.1%
in patients given placebo (between-group difference in ΔHbA 1c = −0.7 ± 0.1%, P < ... Cited by 313 - Related articles - BL Direct - All 8 versions
- ►diabetesjournals.org DJ Drucker - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide
(GIP) exert important effects on β-cells to stimulate glucose-dependent insulin secretion. Both
peptides also regulate β-cell proliferation and cytoprotection. GLP-1, but not GIP, inhibits ... Cited by 284 - Related articles - All 13 versions
- ►endojournals.org A Mari, WM Sallas, YL He, C Watson, M … - Journal of Clinical …, 2005 - Endocrine Soc Results: Vildagliptin significantly increased the insulin secretory rate at 7 mmol/liter glucose
(secretory tone), calculated from the dose response; the difference in least squares mean (
LSM) was 101 ± 51 pmol·min –1 ·m –2 (P = 0.002). The slope of the ß-cell dose response, ... Cited by 198 - Related articles - BL Direct - All 8 versions
- ►physiology.org JJ Holst, J Gromada - American Journal of Physiology- …, 2004 - Am Physiological Soc The available evidence suggests that about two-thirds of the insulin response to an oral glucose
load is due to the potentiating effect of gut-derived incretin hormones. The strongest candidates
for the incretin effect are glucose-dependent insulinotropic polypeptide (GIP) and ... Cited by 180 - Related articles - BL Direct - All 4 versions
T Vilsbøll, JJ Holst - Diabetologia, 2004 - Springer When glucose is taken orally, insulin secretion is stim- ulated much more than it is when glucose
is infused intravenously so as to result in similar glucose con- centrations. This effect, which is
called the incretin ef- fect and is estimated to be responsible for 50 to 70% of the insulin ... Cited by 145 - Related articles - BL Direct - All 7 versions
- ►physiology.org JJ Holst - Physiological reviews, 2007 - Am Physiological Soc Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in the intestinal
epithelial endocrine L-cells by differential processing of proglucagon, the gene which is expressed
in these cells. The current knowledge regarding regulation of proglucagon gene ... Cited by 119 - Related articles - BL Direct - All 5 versions
MA Nauck, JJ Meier - Regulatory peptides, 2005 - Elsevier Glucagon-like peptide 1 (GLP-1) was discovered as an insulinotropic gut hormone, suggesting
a physiological role as an incretin hormone, ie, being responsible, in part, for the higher insulin
secretory response after oral as compared to intravenous glucose administration. This ... Cited by 107 - Related articles - All 6 versions
AM Chang, G Jakobsen, J Sturis, MJ Smith, CJ Bloem, … - Diabetes, 2003 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) stimulates insulin secretion in a glucose-dependent
manner, but its short half-life limits its therapeutic potential. We tested NN2211, a long-acting
GLP-1 derivative, in 10 subjects with type 2 diabetes (means ± SD: age 63 ± 8 years, BMI ... Cited by 94 - Related articles - BL Direct - All 9 versions
JJ Meier, MA Nauck - Diabetes/Metabolism Reviews - interscience.wiley.com Post-translational proteolytic processing of the preproglucagon gene in the gut results in the
formation of glucagon-like peptide 1 (GLP-1). Owing to its glucose-dependent insulinotropic
effect, this hormone was postulated to primarily act as an incretin, ie to augment insulin ... Cited by 73 - Related articles - All 3 versions
